--- title: "EU Seeks Views on Sanofi's Concessions to End Competition Probe — Update" type: "News" locale: "en" url: "https://longbridge.com/en/news/292063120.md" description: "The European Commission is seeking feedback on Sanofi's proposed concessions to resolve an antitrust investigation into alleged disparagement of a rival flu vaccine. Sanofi offered commitments, valid until March 2030, including acknowledging independent vaccine assessments and avoiding negative claims about CSL Seqirus's Fluad. The EU set an August 21 deadline for comments. Sanofi maintains it has acted in full compliance with competition laws." datetime: "2026-07-08T11:46:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292063120.md) - [en](https://longbridge.com/en/news/292063120.md) - [zh-HK](https://longbridge.com/zh-HK/news/292063120.md) --- # EU Seeks Views on Sanofi's Concessions to End Competition Probe — Update By Edith Hancock The European Commission is seeking feedback on a package of concessions that healthcare group Sanofi has offered to end a competition investigation into the company. It comes after the European Union's executive arm started investigating Sanofi in June over concerns it unfairly pursued a campaign to disparage a rival flu vaccine by portraying it as inferior to its own Efluelda. Sanofi said in September 2025 the commission raided its premises over antitrust concerns. The commission said that Sanofi offered to publish statements on its French and German websites acknowledging assessments of the vaccines carried out by the European Centre for Disease Prevention and Control and national immunisation technical advisory groups, and to avoid portraying rival CSL Seqirus's drug Fluad negatively, or claiming that Efluelda is safer or more effective. The company's commitments would be in effect until March 2030, the EU said. "Sanofi remains confident that it has acted, and continues to act, in full compliance with all applicable laws and regulations, including competition law," a company spokesperson said, adding that Sanofi will continue to cooperate with the commission. The regulator set an Aug. 21 deadline to receive feedback on the offer. Write to Edith Hancock at edith.hancock@wsj.com (END) Dow Jones Newswires July 08, 2026 07:32 ET (11:32 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### Related Stocks - [SNY.US](https://longbridge.com/en/quote/SNY.US.md) - [CSLLY.US](https://longbridge.com/en/quote/CSLLY.US.md) - [CSL.AU](https://longbridge.com/en/quote/CSL.AU.md) - [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md) ## Related News & Research - [Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D](https://longbridge.com/en/news/294405008.md) - [Sanofi Drops Dupixent Successor Candidate After Assessing Data](https://longbridge.com/en/news/293787328.md) - [SAN: Q2 2026 saw strong sales and profit growth, led by Dupixent and new launches](https://longbridge.com/en/news/294334114.md) - [Sanofi raises sales outlook on Dupixent strength in boost for new CEO](https://longbridge.com/en/news/294305951.md) - [CSL to start clinical trials for new immunoglobulin manufacturing process](https://longbridge.com/en/news/294130972.md)